According to the Appendix, SOLSTICE met its primary endpoint, demonstrating clinically meaningful HbA1c reductions over 26 weeks in adults with type 2 diabetes. In obesity and overweight, the Phase IIb VISTA trial (NCT06579092) assessed multiple oral doses of elecoglipron versus placebo, using coprimary endpoints of percentage change in body weight and the proportion of participants achieving at least 5% weight loss at 26 weeks
Some patients report that the appetite-suppressing effects feel less pronounced after several months of treatment, though this experience is anecdotal and not well-characterized in the literature for tirzepatide specifically
No detectable nonspecific bands were observed across the full membrane, indicating the high specificity of the antibody
Records are scattered, titration steps are missed, and avoidable prior authorization denials delay therapy
What to Discuss With Your GP Before Taking Both Before commencing treatment with both Ozempic and Topamax, a comprehensive discussion with your GP or specialist is essential
If youve plateaued or the results dont match your goals, staying on a microdose out of comfort is a common trap